• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高龄个体中可溶性尿激酶型纤溶酶原激活物受体水平。

Soluble urokinase plasminogen activator receptor level in individuals of advanced age.

机构信息

Department of Laboratory Diagnostics and Clinical Biochemistry, Medical University of Lodz, Lodz, Poland.

Department of Geriatrics, Medical University of Lodz, Lodz, Poland.

出版信息

Sci Rep. 2020 Sep 22;10(1):15462. doi: 10.1038/s41598-020-72377-w.

DOI:10.1038/s41598-020-72377-w
PMID:32963338
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7508810/
Abstract

Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker whose clinical value has been tested in various groups of patients. The aim of the present study was to determine the suPAR level in a previously uninvestigated population of 182, generally healthy, community-dwelling seniors aged 74-89 years. In addition to suPAR level, selected laboratory parameters of heart and kidney function, lipid and C-reactive protein levels were determined. A group of 45 younger individuals aged 24-66 years was used for comparison. The seniors had higher suPAR levels than younger controls: 3.79 ng/mL (95% CI 3.64-3.96 ng/mL) vs. 3.16 ng/mL (95% CI 2.86-3.45 ng/mL). These levels increased further with advancing age, and were similar in women and men. A multiple regression model confirmed that biomarker level was related to cardiac function, renal function and inflammation, and this remained after adjusting for age. These correlation patterns were similar in older women and men.

摘要

可溶性尿激酶型纤溶酶原激活物受体(suPAR)是一种生物标志物,其临床价值已在各种患者群体中得到验证。本研究的目的是确定 182 名年龄在 74-89 岁、一般健康、居住在社区的老年人中尚未研究过的人群的 suPAR 水平。除 suPAR 水平外,还测定了心脏和肾功能、血脂和 C 反应蛋白水平等选定的实验室参数。将年龄在 24-66 岁的 45 名年轻个体用作对照组。老年人的 suPAR 水平高于年轻对照组:3.79ng/mL(95%CI 3.64-3.96ng/mL)vs.3.16ng/mL(95%CI 2.86-3.45ng/mL)。这些水平随着年龄的增长进一步升高,且在女性和男性中相似。多元回归模型证实生物标志物水平与心脏功能、肾功能和炎症有关,即使在调整年龄后,这种相关性仍然存在。在老年女性和男性中,这些相关性模式相似。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2725/7508810/adc6faacb8bc/41598_2020_72377_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2725/7508810/adc6faacb8bc/41598_2020_72377_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2725/7508810/adc6faacb8bc/41598_2020_72377_Fig1_HTML.jpg

相似文献

1
Soluble urokinase plasminogen activator receptor level in individuals of advanced age.高龄个体中可溶性尿激酶型纤溶酶原激活物受体水平。
Sci Rep. 2020 Sep 22;10(1):15462. doi: 10.1038/s41598-020-72377-w.
2
SuPAR, an emerging biomarker in kidney and inflammatory diseases.尿可溶性髓系细胞触发受体-1,肾脏病和炎症性疾病的一个新兴生物标志物。
Postgrad Med J. 2018 Sep;94(1115):517-524. doi: 10.1136/postgradmedj-2018-135839. Epub 2018 Sep 3.
3
suPAR: A New Biomarker for Cardiovascular Disease?可溶性尿激酶型纤溶酶原激活物受体:心血管疾病的新型生物标志物?
Can J Cardiol. 2015 Oct;31(10):1293-302. doi: 10.1016/j.cjca.2015.03.023. Epub 2015 Mar 25.
4
Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.可溶性尿激酶型纤溶酶原激活物受体可预测 1 型糖尿病患者的心血管事件、肾功能下降和死亡。
Diabetes Care. 2019 Jun;42(6):1112-1119. doi: 10.2337/dc18-1427. Epub 2019 Mar 18.
5
Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.应用 suPAR、CRP 和弗雷明汉风险评分对普通人群进行心血管风险预测。
Int J Cardiol. 2013 Sep 10;167(6):2904-11. doi: 10.1016/j.ijcard.2012.07.018. Epub 2012 Aug 19.
6
Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation.可溶性尿激酶型纤溶酶原激活物受体的年龄价值:作为心肌舒张功能障碍的生物标志物。
BMC Geriatr. 2017 Nov 28;17(1):275. doi: 10.1186/s12877-017-0668-0.
7
Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.循环可溶性尿激酶型纤溶酶原激活物受体可预测普通人群中的癌症、心血管疾病、糖尿病和死亡率。
J Intern Med. 2010 Sep;268(3):296-308. doi: 10.1111/j.1365-2796.2010.02252.x. Epub 2010 May 28.
8
Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.可溶性尿激酶型纤溶酶原激活物受体作为黑人全因死亡率和心血管死亡率的预后标志物。
Int J Cardiol. 2015 Apr 1;184:631-636. doi: 10.1016/j.ijcard.2015.03.041. Epub 2015 Mar 4.
9
Increased soluble urokinase plasminogen activator receptor (suPAR) levels in neovascular age-related macular degeneration: a role for inflammation in the pathogenesis of the disease?新生血管性年龄相关性黄斑变性中可溶性尿激酶型纤溶酶原激活物受体(suPAR)水平升高:炎症在该疾病发病机制中的作用?
Graefes Arch Clin Exp Ophthalmol. 2019 May;257(5):899-903. doi: 10.1007/s00417-018-04230-w. Epub 2019 Jan 7.
10
Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.可溶性尿激酶型纤溶酶原激活物受体与 COPD 患者的动脉僵硬度。
Lung. 2019 Apr;197(2):189-197. doi: 10.1007/s00408-019-00211-w. Epub 2019 Feb 28.

引用本文的文献

1
Salivary levels of suPAR, HIF-1α and TNF-α in different grades of stage III periodontitis.不同分级的III期牙周炎患者唾液中可溶性尿激酶型纤溶酶原激活物受体、缺氧诱导因子-1α和肿瘤坏死因子-α的水平
BMC Oral Health. 2025 May 22;25(1):760. doi: 10.1186/s12903-025-06155-3.
2
Soluble Urokinase-Type Plasminogen Activator Receptor and Inflammatory Biomarker Response with Prognostic Significance after Acute Neuronal Injury - a Prospective Cohort Study.急性神经元损伤后具有预后意义的可溶性尿激酶型纤溶酶原激活物受体及炎症生物标志物反应——一项前瞻性队列研究
Inflammation. 2024 Nov 14. doi: 10.1007/s10753-024-02185-1.
3
Evaluation of Soluble Urokinase Plasminogen Activator Receptor in COVID-19 Patients.

本文引用的文献

1
Risk assessment models for potential use in the emergency department have lower predictive ability in older patients compared to the middle-aged for short-term mortality - a retrospective cohort study.与中年患者相比,急诊科潜在使用的风险评估模型对老年患者短期死亡率的预测能力较低——一项回顾性队列研究。
BMC Geriatr. 2019 May 16;19(1):134. doi: 10.1186/s12877-019-1154-7.
新冠病毒肺炎患者可溶性尿激酶型纤溶酶原激活物受体的评估
J Clin Med. 2024 Oct 23;13(21):6340. doi: 10.3390/jcm13216340.
4
uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence.uPAR 免疫 PET 在胰腺癌、衰老和化疗诱导的衰老中的应用。
J Nucl Med. 2024 Nov 1;65(11):1718-1723. doi: 10.2967/jnumed.124.268278.
5
Establishing reference intervals for soluble urokinase plasminogen activator receptor in Northern European adults.确定北欧成年人可溶性尿激酶型纤溶酶原激活物受体的参考区间。
Pract Lab Med. 2024 Feb 16;39:e00371. doi: 10.1016/j.plabm.2024.e00371. eCollection 2024 Mar.
6
Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection.可溶性尿激酶型纤溶酶原激活物受体(SuPAR)分析在人工关节周围感染诊断中的应用
Antibiotics (Basel). 2024 Feb 12;13(2):179. doi: 10.3390/antibiotics13020179.
7
The predictive value of modified soluble urokinase plasminogen activator receptor (suPAR) with National Early Warning Score (NEWS) for mortality in emergency elderly patients in Japan: a prospective pilot study.改良可溶性尿激酶型纤溶酶原激活物受体(suPAR)联合国家早期预警评分(NEWS)对日本老年急诊患者死亡率的预测价值:一项前瞻性试点研究。
Acute Med Surg. 2023 May 30;10(1):e840. doi: 10.1002/ams2.840. eCollection 2023 Jan-Dec.
8
Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Biomarker Associated with Left Ventricular Hypertrophy in the Elderly, Specifically in Women.可溶性尿激酶型纤溶酶原激活物受体(suPAR)是一种与老年人左心室肥厚相关的生物标志物,在女性中尤为明显。
J Clin Med. 2023 May 5;12(9):3290. doi: 10.3390/jcm12093290.
9
Serum Levels of Urokinase Plasminogen Activator Receptor (suPAR) Discriminate Moderate Uncontrolled from Severe Asthma.血清尿激酶型纤溶酶原激活物受体(suPAR)水平可区分中度未控制哮喘与重度哮喘。
J Pers Med. 2022 Oct 28;12(11):1776. doi: 10.3390/jpm12111776.
10
Ability of combined soluble urokinase plasminogen activator receptor to predict preventable emergency attendance in older patients in Japan: a prospective pilot study.联合可溶性尿激酶型纤溶酶原激活物受体预测日本老年患者可预防急诊就诊的能力:一项前瞻性试点研究。
PeerJ. 2022 Nov 4;10:e14322. doi: 10.7717/peerj.14322. eCollection 2022.